As coordinator of the European project, IrsiCaixa brings together for the second time all MISTRAL partners to discuss the current status of the project, which aims to decipher the role of the intestinal microbiome in the pathology and cure of HIV infection
On October 20 and 21, the follow-up meeting of the European project MISTRAL took place at the Casa-Palau Macaya of the “la Caixa” Foundation. The mission of this European project is to classify, according to the composition of their microbiome, people at risk of acquiring HIV-1, suffering chronic complications related to HIV-1 infection, presenting resistance to antimicrobial drugs and not developing a response to therapeutic vaccination against HIV-1.
The 33 researchers and management staff of the institutions involved in the project –IrsiCaixa AIDS Research Institute, IHU Méditerranée Infection, Centre of Excellence for Health, Immunity and Infections CHIP (RegionH), Case Western Reserve University, Karolinska Institutet, Projecte dels NOMS-Hispanosida, ISGlobal Barcelona Institute for Global Health, AELIX Therapeutics SL– met to discuss the evolution of the different MISTRAL workpackages. Specifically, basic research results were discussed regarding the correlation of the microbiome with HIV-1 control, as well as the impact of antiretroviral therapies and vaccines on the microbiome itself. The operation of the software that allows stratification of the people participating in the study was also analysed. The meeting ended with a discussion of the future steps to be taken in the project.